PHIL, Inc.

We're proud to be featured in a new deep-dive by Digital Medicine Society (DiMe) that showcases our mission to rewriting the rules of #DirectTPatient (DTP) care through cutting edge, data-driven technology that's built to improve access, affordability, and adherence at scale. “In everything we do, we lead with doing what’s right for the patient,” Josh Zeidman, SVP Business Development at PHIL, Inc., said. “We help manufacturers operationalize the ideal approach that makes most sense for their patients.” Read the full piece to learn how we're helping to shape what innovative direct-to-patient care looks like in #Pharma: https://lnkd.in/ejPBUtEV

New insights from the field! Following our recent survey about what patients want from pharma's #DirectToPatient programs, we're sharing what #HealthcareProviders had to say. We're thrilled to release our brand-new research report based on a nationwide survey of 200+ healthcare providers, exploring their perspectives on today's digital access channels, and where the biggest opportunities lie. Read the full report: https://lnkd.in/gdziSe-u

Big announcement! After seeing 20x growth in cash-pay dispenses in 2025, we’ve made a major strategic investment in our cash dispense capabilities, helping pharma operationalize their #DirectToPatient programs at scale.    "With a nationwide network licensed in all 50 states that serves over a million patients each year, [these enhanced capabilities] take this strong foundation to the next level, giving our pharma partners the ability to meet the explosive growth of direct-to-patient access." - Robert Schumaker, VP of Pharmacy Network & Operations at PHIL. Read the press release:  https://lnkd.in/grEC4ZUY

Exciting news! We're thrilled to be partnering with Digital Medicine Society (DiMe) and their esteemed lineup of pharma leaders to establish an category-defining blueprint for #DirectToPatient success. "A well-designed DTP program transforms the prescription access experience from a transaction into a relationship," PHIL, Inc.'s SVP Business Development, Josh Zeidman, said about the expected impact of the program. Read more about the engagement in an exclusive in Fierce Pharma: https://lnkd.in/ewMFGM52

Big news 🎉 PHIL is partnering with Tenpoint Therapeutics to support the launch of a Direct‑to‑Patient cash program for YUVEZZI™, helping to make presbyopia treatment more accessible and affordable. “We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI™— a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what’s possible when patient access is a top priority.” – Deepak Thomas, CEO & Founder, PHIL Read the full press release here: https://lnkd.in/gtceEDkd

That's a wrap on #AccessUSA! We had a fantastic time onstage with Tony and Ash to discuss where #DirectToPatient is today and where it's headed. For those who joined us, many thanks for your participation! We hope you found the conversation insightful, and left feeling energized about what's next.

It's a busy week for the PHIL, Inc. team! We'll be at #DCLF in Miami for the first half of the week, then over to Informa's #AccessUSA conference in Philly. If you'll be onsite at Access USA, swing by Booth #211 and tune into our insights-packed #DirectToPatient panel at 10am EST on March 18, with leading experts to discuss where the DTP programs are at and where pharma is headed next: https://lnkd.in/gpajEsxs We hope to meet you there!

We're thrilled to share that our new research was picked up by Fierce Pharma! Read the exclusive here: https://lnkd.in/gSyXe5K9

Direct-to-patient (DTP) programs are one of pharma's most powerful levers for improving patient starts, adherence, and outcomes. But are current programs built around what truly drives value for today's patients? We surveyed 1,049 U.S. patients to find out — and today we're sharing the results in PHIL, Inc.'s new, groundbreaking research report. The data highlights actionable opportunities for manufacturers investing in DTP programs. Here are some key findings: ▫️ 6 in 10 patients never fill a prescription they're interested in - with access and affordability barriers cited as the top reasons for abandonment. ▫️ 32% of patients prefer a fully digital or hybrid medication access experience, and 1 in 3 won't pursue a medication if they can't get it through their preferred channel. ▫️ 95% of patients want DTP programs to mirror eCommerce experiences, and 60% say manufacturer branding is important for earning their trust. Read the full research report here: https://lnkd.in/gCiGiBcc #DirectToPatient #Pharma #HealthcareInnovation #PatientExperience #PatientAccess 

One-size-fits-all DTP programs leave commercial opportunity on the table, with often patients navigating a system that isn't custom-fit to their needs. Our latest co-authored publication, by Sprout Pharmaceuticals, Inc.'s CEO & Founder, Cindy Eckert, and PHIL, Inc.'s SVP Client Success, Allison Bridges, makes the case for a necessary evolution in #DirectToPatient 2.0: hybrid programs centered around creating a best-in-class patient experience. Hybrid DTP programs address this by giving patients multiple access pathways with transparent, affordable pricing and adherence support built in, while giving commercial teams precise control over #GrossToNet performance. Read the full publication: https://lnkd.in/gCj3EydG #Pharma #DirectToPatient #CommercialStrategy #PatientExperience Drug Channels Institute, an HMP Global Company